You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Mallinckrodt
Baxter
Harvard Business School
Boehringer Ingelheim

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,421,265


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,421,265 protect, and when does it expire?

Patent 9,421,265 protects SIMBRINZA and is included in one NDA.

This patent has forty-one patent family members in twenty-five countries.

Summary for Patent: 9,421,265
Title:Aqueous pharmaceutical compositions containing borate-polyol complexes
Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
Inventor(s): Kabra; Bhagwati P. (Euless, TX)
Assignee: Alcon Research, LTD. (Fort Worth, TX)
Application Number:14/690,617
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,421,265

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis SIMBRINZA brimonidine tartrate; brinzolamide SUSPENSION/DROPS;OPHTHALMIC 204251-001 Apr 19, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,421,265

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077126   Start Trial
Australia 2010262898   Start Trial
Brazil PI1015996   Start Trial
Canada 2763778   Start Trial
Chile 2010000634   Start Trial
China 102802604   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Harvard Business School
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.